

Original research Articles

TOXICOLOGICAL EVALUATION OF SOME ARTEMISININ COMBINATION THERAPIES (ACTs) ON THE KIDNEY AND LIVER OF ALBINO WISTAR RATS

ABSTRACT (ARIAL, BOLD, 11 FONT, LEFT ALIGNED, CAPS)

World Health Organisation (WHO) recommends the use of artemisinin-based combination therapies (ACTs) as drug of choice for the treatment of malaria in endemic regions of the world. This study was designed to evaluate the effects of therapeutic doses of ACTs: Artesunate (Artesunat[®]), Artesunate-Mefloquine (Artequin[®]), Artemether-Lumefantrine (Coartem[®]) and Dihydroartemisinin-Piperaquine (P-Alaxin[®]) on the integrity of the liver and kidneys of albino Wistar rats. Thirty (30) albino Wistar rats weighing between 200g – 280g were randomly divided into 5 groups with 6 animals per group. Group 1 served as control (CTR) while Group 2 received artesunate (AS) for 5 days. Groups 3, 4 and 5 received therapeutic doses of artequin (AQ), coartem (CT) and p-alaxin (PA) respectively for 3 days. The animals were sacrificed under chloroform anaesthesia and blood samples obtained through cardiac puncture for biochemical investigations. Serum ALT activity of Groups 2 and 3 were significantly elevated ($p < 0.05$) while Groups 4 and 5 experienced marginal increase. Group 4 also showed significant increase in total bilirubin though it was marginally increased in all other groups when compared to the control. Creatinine levels were marginally increased in all groups while the urea levels were relatively stable across all groups except in Group 3 where significant increase was observed. The results therefore indicate possible hepatic injury and renal toxicity in albino Wistar rats hence the need for caution and proper attention while undergoing malaria treatment with ACTs.

Keywords: Malaria, Artemisinin-Based Combination Therapies (ACTs), Liver, Kidney and Toxicity

1. INTRODUCTION

Malaria remains one of the greatest causes of mortality and morbidity in the world. Globally, there are between 300 – 500 million cases of clinical malaria every year with 85% of these from Africa. Currently, 1.5 to 2.7 million deaths are attributed to malaria annually, 90% of them in Africa [1]. In Nigeria, malaria is holoendemic hence clinical cases of the disease are seen throughout the year. It is the commonest cause of out-patient hospital attendance in all age groups in the country. Studies have revealed that the readily available and cheap antimalarial drugs: chloroquine and sulphadoxine-pyrimethamine are no longer efficacious in the treatment of malaria in Nigeria due to the development of resistant to these agents [2][3]. Prompt and adequate treatment with an effective antimalarial drug is an essential strategy to reduce the morbidity and mortality resulting from malaria infections. Presently, artemisinin-based combination therapy is the drug of choice for the treatment of malaria in the country and this has proven to be effective in combating the disease. The rationale for the use of ACTs is to reduce the probability of resistant developing simultaneously to the two drugs with independent mechanism of action [3].

The artemisinins are developed from the Chinese wormwood (*Artemisia annua*) and the derivatives namely; artemether, artesunate and dihydroartemisinin have now gained popularity as short acting drugs which could be used in combination with drugs which have longer half-life [4]. Artemether-lumefantrine, artesunate-mefloquine, dihydroartemisinin-piperaquine alongside artesunate are among the commercially available artemisinin-based antimalarial therapies. ACTs have been reported to be safe and efficacious in the treatment of uncomplicated malaria in Nigeria and other countries [1] [5] [6] [7].

Artemisinin and its derivatives have a short half life while the other drugs in ACTs are often with longer half life hence the risk of drug resistant is substantially reduced. Artemisinins are considered to have high safety margins, however, they may be toxic under certain conditions [8] and when used in combination as ACTs on renal function [9]. This study was designed to evaluate and compare the

toxicities of ACTs; artemether-lumefantrine, artesunate-mefloquin, dihydroartemisinin-piperaquin and artesunate on the liver and kidney of albino Wistar rats. These organs are involved in the metabolism and elimination of drugs as such they are susceptible to drug induced injuries.

2. MATERIAL AND METHODS

2.1 Materials

Artemether-lumefantrine (Coartem 80mg/480mg), Artesunate-Mefloquin (Atequin 600mg/750mg), Dihydroartemisinin-piperaquin (P-Alaxin 40mg/320mg) and Artesunate (Artesunat 50mg) were purchased from Tonay Pharmacy, Itu Road, Uyo, Akwa Ibom State, Nigeria. Reagents used for analysis were gotten from Randox Laboratories Ltd, UK. All reagents and chemicals were of analytical grades.

2.2 Experimental Design and Treatment of Animals

Thirty (30) albino Wistar rats weighing between 200g - 280g were randomly divided into 5 groups with 6 animals per group. The rats were kept in standard cages and laboratory conditions, and were fed with normal rat pellets and water *ad libitum*. Group 1 served as control while Groups 2 – 5 were administered therapeutic doses of ACTs as shown in Table 1.

Table 1: Administration of ACTs to Groups 2 – 5

GROUPS	ACT BRAND	DOSAGE	DURATION
2. AS	Artesunat [®]	1.43 mg of artesunate per kg b.w of rat.	Twice on day 1 followed by once daily from day 2 to 5
3. AQ	Artequin [®]	2.86 mg of artesunate and 3.57 mg of mefloquine per kg b.w of rat.	Daily for 3days
4. CT	Coartem [®]	1.14 mg of artemether and 6.86 mg of lumefantrine per kg b.w of rat.	Twice daily for 3days
5. PA	P-Alaxin [®]	1.71 mg of dihydroartemisinin and 13.71mg of piperaquine per b.w of rat.	Once daily for 2 days followed by two third of the dosage on day 3

24 hours after the last dosage, the animals were sacrificed under chloroform anaesthesia. Blood samples were removed through cardiac puncture into a plain sample bottle. Serum was gotten from the blood by centrifugation and then preserved for biochemical investigations.

2.3 Estimation of Biochemical Parameters

Serum ALT activity was assayed based on the method developed by Wroblewski and Ladue (1956) [10], while the method of Dumas and Briggs (1972) [11] was used to assay AST activity. The method of Bowers and McComb (1966) [12] was used to estimate ALP activity in the serum. Determination of total bilirubin (TB) concentration was carried out according to the method of Jendrassik and Grof, (1938) [13]. Serum urea and creatinine concentration were estimated based on the methods of Tobacco *et al* (1979) [14] and Narayanan and Appleton (1980) [15] respectively.

2.4 Statistical Analysis

The data from biochemical analysis were subject to one way analysis of variance (ANOVA) and Student's T-test using SPSS package. Values ($P < 0.05$) were considered significant against the control.

3. RESULTS AND DISCUSSION

3.1 Results

Table 2: Serum Enzyme Activities of Albino Wistar Rats Administered with Different ACTS

GROUPS	ALT (U/L)	AST (U/L)	ALP (U/L)
1. CTR	16.04 ± 3.20	16.36 ± 4.31	36.99 ± 1.68
2. AS	20.29 ± 3.54*	13.93 ± 4.66	24.67 ± 3.03*
3. AQ	20.32 ± 3.09*	12.40 ± 1.87*	35.32 ± 2.31
4. CT	18.90 ± 4.70	12.00 ± 3.68*	37.37 ± 3.84
5. PA	18.90 ± 5.57	15.26 ± 3.99	28.86 ± 5.77*

Values are presented as mean ± standard deviation. * = significantly different from control (p<0.05). Number of rats (n) = 6.

Table 3: Effect of Administration of ACTs on Urea, Creatinine and Bilirubin Concentration in Albino Wistar Rats

GROUPS	CREATININE (μmol/l)	UREA (mmol/l)	TOTAL BILIRUBIN (μmol/l)	CONJ. BILIRUBIN (μmol/l)
1. CTR	84.21 ± 20.39	3.01 ± 0.36	22.90 ± 4.30	6.10 ± 2.10
2. AS	87.42 ± 18.05	2.51 ± 0.77	23.38 ± 4.00	5.17 ± 1.77
3. AQ	89.84 ± 28.92	3.76 ± 0.40*	23.60 ± 4.57	3.53 ± 1.75*
4. CT	106.82 ± 30.75	2.75 ± 2.31	29.40 ± 3.21*	6.52 ± 2.70
5. PA	101.82 ± 32.25	3.03 ± 0.74	24.79 ± 4.00	5.12 ± 2.09

Values are presented as mean ± standard deviation. * = significantly different from control (p<0.05). Number of rats (n) = 6.

3.2 Discussion

Hepatocyte membrane distortion is associated with membrane leakage of the hepatocyte cytosolic contents which is manifested by significant elevation of serum/plasma enzymes namely; ALT, AST and ALP [16]. These enzymes serve as biomarkers for evaluation of hepatocellular damage, however, ALT is the most reliable. AST is known to be abundant in the cardiac muscle, skeletal muscle, kidney and testes thus any disease affecting any of these extra hepatic tissues significantly elevates the serum level of the enzyme [17]. The observed significant increase in ALT activity in Groups 2 and 3 indicates possible drug induced hepatic damage or hepatotoxicity in the albino Wistar rats. This is in collaboration with other studies where the effects of P-Alaxin and Coartem on pregnant albino Wistar rats were evaluated [18] [19] [20].

Furthermore, a study by Ofem *et al*, (2014) [21] reported that activities of serum ALT, AST and ALP increased significantly upon the administration of Coartem and P-Alaxin on albino Wistar rats. Elevation of serum enzyme activities can also be attributed to causes other than liver injury such as muscle damage. These enzymes exist as isoenzymes which originates from other tissues hence the need for evaluation of other biomarkers of liver function. Total bilirubin was found to be significantly elevated in coartem treated group, suggestive of hepatobiliary injury. There were non-significant increases in total bilirubin in other groups. Intravascular haemolysis of red blood cells due to drug treatment has been reported. In particular, quinine based drug, when used for chemoprophylaxis has been shown to stimulate the production of drug dependent complement fixing capable of causing intravascular red cell lyses [22].

Elevated levels of creatinine and urea in serum are an indication of poorly functioning kidneys and malfunctioning such as impairment of glomerular filtration. A rise in blood creatinine is observed only with marked damage to functioning nephrons [23]. This study revealed a non-significant increase in the levels of creatinine in all groups while urea was significantly increased in artequin treated group. However, a better evaluation of kidney function would be through a creatinine clearance test as suggested by American Diabetes Association [24].

4. CONCLUSION

Summarily, it can be concluded from this study that ACT therapies can have deleterious effect on the kidney and liver. Furthermore, dihydroartemisinin-piperaquin has the best safety profile among the ACTs studied while artemether-lumefantrine and artesunate-mefloquin are more likely to induce significant toxicological effects.

REFERENCES

- Agomo PU, Mustapha RAS, Omoloye BG, Okechukwu AN, Mafe AG, Ijale, SI, et al. Efficacy and Safety of Artesunate + Mefloquin (Artequin) in the Treatment Of Uncomplicated falciparum Malaria in Ijede Community, Ikorodu LGA, Lagos State, Nigeria. *Journal of Medicinal Sciences*, 2007;7(5):816-824.
- Ekanem OJ, Weisfeld LA, Salako, Nahlen M.U. Sensitivity of *Plasmodium falciparum* to Chloroquine and Sulphadoxine-Pyrimethamine in Nigerian Children. *Bulletin of World Health Organisation*, 1990;68:45-52.
- White NJ. Delaying Antimalarial Drug Resistance with Combination Chemotherapy. *Parasitology*, 1999;41:301–308.
- White NJ, Olliaro P. Artemisinin and Derivatives in the Treatment of Uncomplicated Malaria. *Tropical Medicine*, 1998;58:54–56.
- Mayxay M, Thongpraseuth V, Khanthavong M, Lindergardh N, Barends M, Keola S, et al. An Open Randomised Comparison of Artesunate plus Mefloquin vs Dihydroartemisinin-Piperaquin for the Treatment of Uncomplicated *Plasmodium falciparum* Malaria in the Lao People's Democratic Republic (Laos). *Tropical Medicine and International Health*, 2006;11(8):1157-1165.
- Frey SG, Chelo D, Kinkela MN, Djouknone F, Tietche F, Hatz, C. et al. Artesunate-Mefloquin Combination Therapy in Acute *Plasmodium falciparum* Malaria in Young Children: A Field Study Regarding Neurological and Neuropsychiatric Safety. *Malaria Journal*, 2010;9:291-299.
- Olayemi SO, Anikawe AP, Akinyede A, Oreagba AI, Awodele O. Effect of Malarial Treatment on Biochemical Parameters and Plasma pH of Mice Infected with *Plasmodium berghei*. *International Journal of Pharmacology*, 2012;8:549-553.
- Udobre A, Edoho EJ, Eseyin O, Etim EJ. Effect of Artemisinin with Folic Acid on the Activities of Aspartate Aminotransferase, Alanine Aminotransferase and Alkaline Phosphatase in Rats. *Asian Journal of Biochemistry*, 2009;4:55-59.
- Etim EI, Udoh IE, Udoh AE. Evaluation of Plasma Creatinine and Urea after Oral Administration of Artemisinin and some Artemisinin Combination Therapy Regimen on Healthy Nigerian Males. *World Journal of Applied Sciences and Technology*, 2012;4:1–6.
- Wroblewski F, Ladue JS. Serum Glutamic Pyruvic Transaminase in Cardiac and Hepatic Disease. *Proceedings of the Society for Experimental Biology and Medicine*, 1956;91:569.
- Doumas B, Briggs HG. *Standard Methods of Clinical Chemistry*. London Academic Press, New York; 1972.
- Bowers GN, McComb RB. A Continuous Spectrophotometric Method for measuring the Activity of Serum Alkaline Phosphatase. *Clinical Chemistry*, 1966;12:70
- Jendrassik, L. and Grof, P. (1938). Colorimetric Method of determination of Bilirubin. *Biochemistry*, 297:81–82.
- Tobacco A, Meiatini F, Moda E, Tarli P. Simplified Enzymatic/Colorimetric Serum Urea Nitrogen determination. *Clinical Chemistry*, 1979;25:336.
- Narayanan S, Appleton HD. Creatinine: A Review. *Clinical Chemistry*. 1980;26:1119–1126.
- Bhattacharya M, Western V, Pan K. Elevation of Serum/Plasma Enzymes of Acute Hepatocellular Damage. *Clinical Pharmacology and Therapeutics*, 2003;41(7):16–19.
- Olayinka ET, Ore A. Alteration in Antioxidant Status and Biochemical Indices following administration of Dihydroartemisinin-Piperaquin Phosphate (P-Alaxin). *IOSR Journal of Pharmacy and Biological Sciences*, 2013;5(4):43-53.
- Farombi A, Ademola B, Olatunde M. Effect of Coartem and P-Alaxin on Pregnant Albino Wistar Rats. *Asian Journal of Biochemical Science*, 2000;16(7):66–69.

- 174 19. Obi E, Orisakwe OE, Asongha LA, Udemezue OO, Orish VN. The Hepatotoxic Effect of
175 Halofrantrine in Guinea Pigs. *Indian Journal Pharmacology*, 2014;26:303-305
- 176 20. Akam U, Okon E, Edem E. Effect of Chloroquine, Amodiaquine, Quinine and Halofantrine on
177 Serum Enzymes. *Journal of Pharmacy and Biological Sciences*, 2013;15(8):33–35.
- 178 21. Ofem OE, Nna VU, Archibong AN. Comparative Effects of Two Antimalarial Drugs (P-Alaxin and
179 Coartem) on Serum Electrolytes and Serum Enzymes in Albino Wistar Rats. *Research Journal of
180 Pharmaceutical, Biological and Chemical Sciences* 2014;5(1):54–63.
- 181 22. Weatherall DJ, Miller LH, Baruch DI, Marsh K, Doumbo OK, Gasals-Pascual C, et al. Malaria and
182 the Red Cell. In: *Haematology. American Society of Haematology Education Program Book*;
183 2002.
- 184 23. Etim OE, Akpan EJ, Akpanabiatu MI, Iba U, Bassey UE. Effect of Co-administration of
185 Chloroquine and Cefuroxime on Kidney Function in Albino Wistar Rats. *Journal of Physiology and
186 Pharmacological Advances*, 2014;4(8):407–412.
- 187 24. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic
188 Nephropathy: Diagnosis, Prevention, and Treatment. *Diabetes Care*, 2005;28(1):164–76.